DOCSLIB.ORG

A Case-Based Evaluation of SRD5A1, SRD5A2, AR, and ADRA1A As Candidate Genes for Severity of BPH

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Case-Based Evaluation of SRD5A1, SRD5A2, AR, and ADRA1A As Candidate Genes for Severity of BPH The Pharmacogenomics Journal (2004) 4, 251–259 & 2004 Nature Publishing Group All rights reserved 1470-269X/04 $30.00 www.nature.com/tpj ORIGINAL ARTICLE A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH M Klotsman1,2 ABSTRACT 3 In men with a clinical diagnosis of benign prostatic hyperplasia (BPH), CR Weinberg polytomous logistic regression analysis was conducted to evaluate associa- 1,4 K Davis tions between two silent polymorphisms in SRD5A1 (codon positions 30 and CG Binnie5 116), two polymorphisms in SRD5A2 (Val89Leu substitution and C to T KE Hartmann1 transition in intron 1), a trinucleotide (CAG)n repeat in androgen receptor (AR), and an Arg492Cys substitution in ADRA1A and clinical parameters that 1Department of Epidemiology, University of characterize severity of BPH. Candidate gene selection was based on two North Carolina School of Public Health, Chapel mechanistic pathways targeted by pharmacotherapy for BPH: (1) androgen 2 Hill, NC, USA; Genetics Research, metabolic loci contributing to prostate growth (static obstruction); and (2) GlaxoSmithKline, RTP, NC, USA; 3Biostatistics Branch, National Institute of Environmental factors affecting smooth muscle tone (dynamic obstruction). Polymorphisms Health Sciences, RTP, NC, USA; 4World-Wide in SRD5A2 were not associated with severity of BPH; however, SRD5A1 Epidemiology, GlaxoSmithKline, RTP, NC, USA; polymorphisms were associated with severity of BPH. The process(es) in 5 Discovery Genetics, GlaxoSmithKline, RTP, NC, which these silent single-nucleotide polymorphisms (SNPs) influence BPH USA phenotypes is unknown and additional studies will be needed to assess Correspondence: whether these SNPs have direct functional consequences. The characteriza- Dr M Klotsman, PO Box 13398, Five Moore tion of additional molecular factors that contribute to static and dynamic Dr, RTP, NC 27709-3398, USA. obstruction may help predict response to pharmacotherapy and serve to Tel: þ 1 919 483 5249 identify novel drug targets for the clinical management of BPH. Fax: þ 1 919 315 0311 E-mail: [email protected] The Pharmacogenomics Journal (2004) 4, 251–259. doi:10.1038/sj.tpj.6500248 Published online 11 May 2004 Keywords: BPH; prostate; testosterone 5-alpha-reductase; adrenergic alpha-an- tagonists INTRODUCTION Benign prostatic hyperplasia (BPH) is an extremely common condition among aging men that typically manifests as a constellation of lower urinary tract symptoms (LUTS) which are bothersome, impair psychological and functional well-being, and interfere with activities of daily living. Prevalence estimates for BPH vary, but it is clear that BPH is nearly ubiquitous in older men and is a significant health concern.1 Histologic evidence of BPH was found in almost 90% of men in their 80s,2 and it is estimated that nearly one in four men receive treatment for LUTS by the eighth decade of life.3 Despite significant morbidity caused by BPH, the etiology and determinants of severity of this condition remain poorly understood. Received: 24 November 2003 The current BPH literature suggests that LUTS generally result from static Revised: 27 January 2004 Accepted: 19 February 2004 (mechanical) and/or dynamic component(s). The static component is a Published online 11 May 2004 consequence of the benign enlargement of the prostate, which increases pressure Evaluation of candidate genes for severity of BPH M Klotsman et al 252 on the urethra with subsequent obstruction of urine flow. RESULTS Prostate growth is regulated, in part, by a defined androgen- Baseline Distributions dependent pathway,4 which begins with the diffusion of Genetic data were available for 87% of the study participants serum testosterone (TES) into the prostate. In the prostatic (n ¼ 2428 out of 2802) for whom baseline data were available stroma, TES is irreversibly converted to the more active (Table 1). Genotypes were missing primarily because of dihydrotestosterone (DHT) by the enzyme 5a-reductase type failed assays or subject refusal to submit a blood sample for II. Converted DHT then enters epithelial cells and selectively genetic analysis. The baseline characteristics for the subset binds to the androgen receptor (AR), a ligand-dependent of men in whom genetic data were unavailable appeared transcription factor, forming a DHT/AR complex. This similar to those of the study group as a whole (data not complex is translocated into the nucleus and promotes shown). prostatic growth by binding to androgen response elements in the regulatory region of target genes5,6 (eg, androgen regulation of prostate-specific antigen (PSA) expression is mediated by AR).7 Table 1 Baseline clinical parameters and genotype distribu- By contrast, dynamic obstruction is caused by dysfunction tions among 2201 Caucasians of smooth muscle tone in the prostatic capsule surrounding Parameter Mean (7SD) the prostate. Prostatic smooth muscle tone varies according to the sympathetic stimulation of a -adrenoceptors, in 1 Age (yr) 66.577.6 a 8–10 particular, the 1A-adrenoceptor subtype. In a healthy PSA (ng/ml) 3.872.0 male, smooth muscle in the capsule contracts to propel AUA-SI 17.276.0 7 prostatic secretions from storage into the prostatic urethra Qmax (ml/s) 10.4 3.6 during ejaculation. In a BPH disease state, increased smooth Post-void residual volume 79775 muscle tone in the outer prostatic capsule is believed to Total prostate volume (cm3) 54.9723.0 bring on LUTS by increasing urethral resistance. Conse- Transition zone volume (cm3) 26.8717.0 quently, the dynamic component of BPH is determined, at Serum testosterone (pg/ml) 392871489 7 least partially, by a -adrenoceptor activity and prostatic Serum dihydrotestosterone 404 202 1A 7 smooth muscle tone.11 Body mass index 27.8 4.1 Systematic screens of genes encoding for 5a-reductase SRD5A1: Silent Arg 30a type I and II (SRD5A1 and SRD5A2), AR, and a -adreno- 1A G/G 625 (28.6%) ceptor (ADRA1A) have identified polymorphisms that may G/C 1104 (50.6%) influence protein production and/or integrity. These poly- C/C 454 (20.8%) morphic loci can be operationally compartmentalized into one of two pathways that contribute to the severity of BPH: SRD5A1: Silent Ala 116a (1) an androgen-dependent pathway, involving 5a-reductase A/A 874 (40.0%) and AR activity, contributing to static obstruction; and (2) a A/G 1004 (46.1%) G/G 304 (13.9%) non-growth-dependent pathway, mediated by a1A-adreno- ceptor, that may be instrumental in the onset of dynamic b obstruction. The polymorphisms evaluated in this study SRD5A2: Val89Leu Val/Val 1110 (50.9%) included two silent polymorphisms in SRD5A1 (codon 12 Val/Leu 885 (40.6%) positions 30 and 116), two polymorphisms in SRD5A2 Leu/Leu 184 (8.4%) 13,14 (Val89Leu and C to T transition in intron 1), a (CAG)n 15,16 repeat in AR, and Arg492Cys substitution in SRD5A2: Intron 1 C-Tb ADRA1A.17,18 C/C 1065 (49.7%) Pharmacotherapy with a-blockers and 5a-reductase inhi- C/T 880 (41.1%) bitors has become commonplace for the medical manage- T/T 196 (9.2%) ment of BPH.19 Alpha blockers alleviate dynamic obstruction by interrupting motor sympathetic adrenergic ADRA1A: Arg492Leu nerve stimulation in the prostate,20 while 5a-reductase Arg/Arg 630 (28.7%) Arg/Cys 1099 (50.1%) inhibitors limit DHT production resulting in involution of Cys/Cys 464 (21.2%) the prostate.21 Given the importance of a-blockers and 5a- reductase inhibitors in the treatment of BPH, this study was AR: (CAG)n repeats undertaken to evaluate associations between polymorph- (CAG)0–18 82 (6.0%) isms in candidate genes whose effects are targeted by (CAG)19–22 970 (43.9%) pharmacotherapy and clinical parameters used to character- (CAG)423 1103 (50.1%) ize the severity of BPH. Further characterization of poly- a morphic loci hypothesized to play a role in static and The SRD5A1 Arg30 and Ala116 SNPs were not strongly linked (correlation, R ¼ 0.6775). dynamic obstruction precipitated by BPH may help to shed bThe SRD5A2 V89L and Intron 1 C-T SNPs appear to be in linkage disequilibrium light on etiologic mechanisms predisposing men to BPH. (correlation, R ¼ 1). The Pharmacogenomics Journal Evaluation of candidate genes for severity of BPH M Klotsman et al 253 Allele and Genotype Frequencies tion were observed (Table 2). Chi-square statistics were re- Regression analyses performed to evaluate whether candi- calculated for men under the age of 60, to allow for the date genetic markers are associated with severity of BPH possibility that gene-by-gene interaction contributes to an were restricted to Caucasian subjects. The two single- earlier age of onset. In this younger group of men, statistical nucleotide polymorphisms (SNPs) in 5a-reductase type II significance was not reached for any of the gene-by-gene (SRD5A2) are physically close (intron 1 and exon 1) and pairs evaluated (data not shown). were in linkage disequilibrium (LD) (correlation, R ¼ 1). Results based on fitting logistic regression models to relate Concordant SRD5A2 genotype pairs were observed in 93% of three-level genotypes at each polymorphic loci and BPH- study participants, and predominant allele frequencies were related clinical parameters are shown in Table 3. Polymorph- nearly identical (71.2% and 70.3% for 89-Val and intron-C isms in 5a-reductase type II (SRD5A2) did not appear to be alleles, respectively). The SNPs in SRD5A1 were in partial LD associated with the severity of BPH; however, polymorph- (correlation, R ¼ 0.6775). These LD estimates are based on a isms in 5a-reductase type I were associated with severity. case-only population and may not be comparable to LD one The silent Arg30 polymorphism in 5a-reductase type I would observe in the general population. (SRD5A1) was associated with serum TES and DHT levels (P ¼ 0.03 and P ¼ 0.04, respectively), and there was limited Genetic Analysis evidence for an association with maximum urinary flow A total of eight gene-by-gene combinations were evaluated (Qmax; P ¼ 0.09), and post-void residual volume (PVR; to assess the possible synergistic genetic effects of pairs of P ¼ 0.10) (Table 3).
Load more

Recommended publications
  • De Novo Sequencing and Transcriptome Analysis Reveal Key Genes Regulating Steroid Metabolism in Leaves, Roots, Adventitious Roots and Calli of Periploca Sepium Bunge
    ORIGINAL RESEARCH published: 21 April 2017 doi: 10.3389/fpls.2017.00594 De novo Sequencing and Transcriptome Analysis Reveal Key Genes Regulating Steroid Metabolism in Leaves, Roots, Adventitious Roots and Calli of Periploca sepium Bunge Jian Zhang 1, 2, 3, Xinglin Li 1, 3*, Fuping Lu 1, 3, Shanying Wang 1, 3, Yunhe An 4, Xiaoxing Su 4, Xiankuan Li 2, Lin Ma 2 and Guangjian Han 5 1 Key Lab of Industrial Fermentation Microbiology, Tianjin University of Science and Technology, Ministry of Education, Tianjin, China, 2 School of Traditional Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, 3 College of Bioengineering, Tianjin University of Science and Technology, Tianjin, China, 4 Beijing Center for Physical and Chemical Analysis, Beijing, China, 5 Shachuan Biotechnology, Tianjin, China Edited by: Periploca sepium Bunge is a traditional medicinal plant, whose root bark is important Peng Zhang, Institute of Plant Physiology and for Chinese herbal medicine. Its major bioactive compounds are C21 steroids and Ecology, SIBS, CAS, China periplocin, a kind of cardiac glycoside, which are derived from the steroid synthesis Reviewed by: pathway. However, research on P. sepium genome or transcriptomes and their related Kun Yu, genes has been lacking for a long time. In this study we estimated this species Hubei University of Chinese Medicine, China nuclear genome size at 170 Mb (using flow cytometry). Then, RNA sequencing of Jun Yang, four different tissue samples of P. sepium (leaves, roots, adventitious roots, and Shanghai Chenshan Plant Science Research Center (CAS), China calli) was done using the sequencing platform Illumina/Solexa Hiseq 2,500.
    [Show full text]
  • Characterization of the Ergosterol Biosynthesis Pathway in Ceratocystidaceae
    Journal of Fungi Article Characterization of the Ergosterol Biosynthesis Pathway in Ceratocystidaceae Mohammad Sayari 1,2,*, Magrieta A. van der Nest 1,3, Emma T. Steenkamp 1, Saleh Rahimlou 4 , Almuth Hammerbacher 1 and Brenda D. Wingfield 1 1 Department of Biochemistry, Genetics and Microbiology, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria 0002, South Africa; [email protected] (M.A.v.d.N.); [email protected] (E.T.S.); [email protected] (A.H.); brenda.wingfi[email protected] (B.D.W.) 2 Department of Plant Science, University of Manitoba, 222 Agriculture Building, Winnipeg, MB R3T 2N2, Canada 3 Biotechnology Platform, Agricultural Research Council (ARC), Onderstepoort Campus, Pretoria 0110, South Africa 4 Department of Mycology and Microbiology, University of Tartu, 14A Ravila, 50411 Tartu, Estonia; [email protected] * Correspondence: [email protected]; Fax: +1-204-474-7528 Abstract: Terpenes represent the biggest group of natural compounds on earth. This large class of organic hydrocarbons is distributed among all cellular organisms, including fungi. The different classes of terpenes produced by fungi are mono, sesqui, di- and triterpenes, although triterpene ergosterol is the main sterol identified in cell membranes of these organisms. The availability of genomic data from members in the Ceratocystidaceae enabled the detection and characterization of the genes encoding the enzymes in the mevalonate and ergosterol biosynthetic pathways. Using Citation: Sayari, M.; van der Nest, a bioinformatics approach, fungal orthologs of sterol biosynthesis genes in nine different species M.A.; Steenkamp, E.T.; Rahimlou, S.; of the Ceratocystidaceae were identified.
    [Show full text]
  • Association Between Two Polymorphisms in the SRD5A2 Gene and Serum Androgen Concentrations in British Men1
    578 Vol. 12, 578–581, June 2003 Cancer Epidemiology, Biomarkers & Prevention Short Communication Association between Two Polymorphisms in the SRD5A2 Gene and Serum Androgen Concentrations in British Men1 Naomi E. Allen,2 Juergen K. V. Reichardt, are needed to additionally clarify the role of the A49T Hannah Nguyen, and Timothy J. Key polymorphism in androgen metabolism. Cancer Research United Kingdom Epidemiology Unit, University of Oxford, Gibson Building, Radcliffe Infirmary, Oxford, OX2 6HE, United Kingdom Introduction [N. E. A., T. J. K.], and Institute for Genetic Medicine, Departments of Biochemistry and Molecular Biology and Preventive Medicine, University of It is well established that the steroid 5 ␣-reductase type II Southern California School of Medicine, University of Southern California, enzyme, which irreversibly converts testosterone to its more Los Angeles, California 90089-9075 [J. K. V. R., H. N.] potent metabolite DHT3 in prostatic cells, is required for the normal growth and development of the prostate gland (1). A meta-analysis of prospective studies suggests that the serum Abstract concentration of A-diol-g, a serum marker of the abundance of Androgens are essential for the growth of the prostate 5 ␣-reductase type II and intraprostatic DHT, is slightly higher gland and have been implicated in the development of in men who subsequently develop prostate cancer compared prostate cancer. Little is known about the determinants with healthy individuals (2). The circulating A-diol-g concen- of androgen levels in men, although observed ethnic tration is believed to be a more accurate serum marker of 5 differences suggest they may have a genetic basis.
    [Show full text]
  • Type of the Paper (Article
    Supplementary Material A Proteomics Study on the Mechanism of Nutmeg-induced Hepatotoxicity Wei Xia 1, †, Zhipeng Cao 1, †, Xiaoyu Zhang 1 and Lina Gao 1,* 1 School of Forensic Medicine, China Medical University, Shenyang 110122, P. R. China; lessen- [email protected] (W.X.); [email protected] (Z.C.); [email protected] (X.Z.) † The authors contributed equally to this work. * Correspondence: [email protected] Figure S1. Table S1. Peptide fraction separation liquid chromatography elution gradient table. Time (min) Flow rate (mL/min) Mobile phase A (%) Mobile phase B (%) 0 1 97 3 10 1 95 5 30 1 80 20 48 1 60 40 50 1 50 50 53 1 30 70 54 1 0 100 1 Table 2. Liquid chromatography elution gradient table. Time (min) Flow rate (nL/min) Mobile phase A (%) Mobile phase B (%) 0 600 94 6 2 600 83 17 82 600 60 40 84 600 50 50 85 600 45 55 90 600 0 100 Table S3. The analysis parameter of Proteome Discoverer 2.2. Item Value Type of Quantification Reporter Quantification (TMT) Enzyme Trypsin Max.Missed Cleavage Sites 2 Precursor Mass Tolerance 10 ppm Fragment Mass Tolerance 0.02 Da Dynamic Modification Oxidation/+15.995 Da (M) and TMT /+229.163 Da (K,Y) N-Terminal Modification Acetyl/+42.011 Da (N-Terminal) and TMT /+229.163 Da (N-Terminal) Static Modification Carbamidomethyl/+57.021 Da (C) 2 Table S4. The DEPs between the low-dose group and the control group. Protein Gene Fold Change P value Trend mRNA H2-K1 0.380 0.010 down Glutamine synthetase 0.426 0.022 down Annexin Anxa6 0.447 0.032 down mRNA H2-D1 0.467 0.002 down Ribokinase Rbks 0.487 0.000
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Effects on Steroid 5-Alpha Reductase Gene Expression of Thai Rice Bran Extracts and Molecular Dynamics Study on SRD5A2
    biology Article Effects on Steroid 5-Alpha Reductase Gene Expression of Thai Rice Bran Extracts and Molecular Dynamics Study on SRD5A2 Chiranan Khantham 1 , Wipawadee Yooin 1,2 , Korawan Sringarm 2,3 , Sarana Rose Sommano 2,4 , Supat Jiranusornkul 1, Francisco David Carmona 5,6 , Wutigri Nimlamool 7 , Pensak Jantrawut 1,2, Pornchai Rachtanapun 8,9 and Warintorn Ruksiriwanich 1,2,8,* 1 Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; [email protected] (C.K.); [email protected] (W.Y.); [email protected] (S.J.); [email protected] (P.J.) 2 Cluster of Research and Development of Pharmaceutical and Natural Products Innovation for Human or Animal, Chiang Mai University, Chiang Mai 50200, Thailand; [email protected] (K.S.); [email protected] (S.R.S.) 3 Department of Animal and Aquatic Sciences, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand 4 Plant Bioactive Compound Laboratory (BAC), Department of Plant and Soil Sciences, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand 5 Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain; [email protected] 6 Instituto de Investigación Biosanitaria ibs.GRANADA, 18014 Granada, Spain 7 Citation: Khantham, C.; Yooin, W.; Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Sringarm, K.; Sommano, S.R.; [email protected] 8 Cluster of Agro Bio-Circular-Green Industry, Faculty of Agro-Industry, Chiang Mai University, Jiranusornkul, S.; Carmona, F.D.; Chiang Mai 50100, Thailand; [email protected] Nimlamool, W.; Jantrawut, P.; 9 School of Agro-Industry, Faculty of Agro-Industry, Chiang Mai University, Chiang Mai 50100, Thailand Rachtanapun, P.; Ruksiriwanich, W.
    [Show full text]
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
    [Show full text]
  • Crystal Structure of Steroid Reductase SRD5A Reveals Conserved Steroid Reduction Mechanism
    ARTICLE https://doi.org/10.1038/s41467-020-20675-2 OPEN Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism Yufei Han 1,9, Qian Zhuang2,9, Bo Sun3,9, Wenping Lv 4,9, Sheng Wang5,9, Qingjie Xiao6, Bin Pang1, ✉ Youli Zhou1, Fuxing Wang1, Pengliang Chi6, Qisheng Wang3, Zhen Li7, Lizhe Zhu 4, Fuping Li8, Dong Deng6 , ✉ ✉ ✉ Ying-Chih Chiang 1 , Zhenfei Li 2 & Ruobing Ren 1 Steroid hormones are essential in stress response, immune system regulation, and repro- 1234567890():,; duction in mammals. Steroids with 3-oxo-Δ4 structure, such as testosterone or progesterone, are catalyzed by steroid 5α-reductases (SRD5As) to generate their corresponding 3-oxo-5α steroids, which are essential for multiple physiological and pathological processes. SRD5A2 is already a target of clinically relevant drugs. However, the detailed mechanism of SRD5A- mediated reduction remains elusive. Here we report the crystal structure of PbSRD5A from Proteobacteria bacterium, a homolog of both SRD5A1 and SRD5A2, in complex with the cofactor NADPH at 2.0 Å resolution. PbSRD5A exists as a monomer comprised of seven transmembrane segments (TMs). The TM1-4 enclose a hydrophobic substrate binding cavity, whereas TM5-7 coordinate cofactor NADPH through extensive hydrogen bonds network. Homology-based structural models of HsSRD5A1 and -2, together with biochemical char- acterization, define the substrate binding pocket of SRD5As, explain the properties of disease-related mutants and provide an important framework for further understanding of the mechanism of NADPH mediated steroids 3-oxo-Δ4 reduction. Based on these analyses, the design of therapeutic molecules targeting SRD5As with improved specificity and therapeutic efficacy would be possible.
    [Show full text]
  • Late Diagnosis of 5Alpha Steroid-Reductase Deficiency Due to IVS12A>G Mutation of the Srd5a2 Gene in an Adolescent Girl Presented with Primary Amenorrhea
    HORMONES 2011, 10(3):230-235 Case Report Late diagnosis of 5alpha steroid-reductase deficiency due to IVS12A>G mutation of the SRD5a2 gene in an adolescent girl presented with primary amenorrhea Nicos Skordis,1,2 Christos Shammas,2 Elisavet Efstathiou,1 Amalia Sertedaki,3 Vassos Neocleous,2 Leonidas Phylactou2 1Pediatric Endocrine Unit, Makarios Hospital, Nicosia, Cyprus, 2Department of Molecular Genetics Function & Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, 3Unit of Endocrinology, Diabetes and Metabolism, First Department of Pediatrics, Athens University, Medical School, Athens, Greece ABSTRACT BACKGROUND: The clinical spectrum of 5α-reductase deficiency, caused by mutations in the SRD5A2 gene, ranges from complete female appearance of the external genitalia at birth to nearly complete male phenotype. CASE REPORT: A 14-year-old girl presented with primary amenorrhea (PA) and lack of breast development. She was 173 cm in height, had an increased amount of pubic hair and clitoromegaly (3 cm), with a 4 cm blind vaginal pouch. Gonads were palpable in the inguinal canal bilaterally and no uterus was identified on ultrasound. C hromosomal analysis showed a 46,XY karyotype. The Testosterone/DHT ratio was high (16.5) and further increased to 29.4 after stimulation with hCG, thus favouring the diagnosis of 5α-reductase deficiency. Since the issue of gender change was not considered, gonadectomy was performed followed by successful feminisation with hormonal replacement therapy. GE- NETIC STUDIES: Molecular analysis of the SRD5A2 gene by DNA sequencing of all 5 exons revealed the presence of the splice mutation A>G at position -2 of the acceptor site of intron 1/exon 2 (IVS1-2A>G) in homozygosity.
    [Show full text]
  • Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
    International Journal of Molecular Sciences Article Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway Patricia Rodríguez Castaño 1,2, Shaheena Parween 1,2 and Amit V Pandey 1,2,* 1 Pediatric Endocrinology, Diabetology, and Metabolism, University Children’s Hospital Bern, 3010 Bern, Switzerland; [email protected] (P.R.C.); [email protected] (S.P.) 2 Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland * Correspondence: [email protected]; Tel.: +41-31-632-9637 Received: 5 September 2019; Accepted: 16 September 2019; Published: 17 September 2019 Abstract: Turmeric, a popular ingredient in the cuisine of many Asian countries, comes from the roots of the Curcuma longa and is known for its use in Chinese and Ayurvedic medicine. Turmeric is rich in curcuminoids, including curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Curcuminoids have potent wound healing, anti-inflammatory, and anti-carcinogenic activities. While curcuminoids have been studied for many years, not much is known about their effects on steroid metabolism. Since many anti-cancer drugs target enzymes from the steroidogenic pathway, we tested the effect of curcuminoids on cytochrome P450 CYP17A1, CYP21A2, and CYP19A1 enzyme activities. When using 10 µg/mL of curcuminoids, both the 17α-hydroxylase as well as 17,20 lyase activities of CYP17A1 were reduced significantly. On the other hand, only a mild reduction in CYP21A2 activity was observed. Furthermore, CYP19A1 activity was also reduced up to ~20% of control when using 1–100 µg/mL of curcuminoids in a dose-dependent manner. Molecular docking studies confirmed that curcumin could dock onto the active sites of CYP17A1, CYP19A1, as well as CYP21A2.
    [Show full text]
  • Disruption of Androgen Metabolism, Regulation and Effects: Involvement of Steroidogenic Enzymes
    Disruption of Androgen Metabolism, Regulation and Effects: Involvement of Steroidogenic Enzymes Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Cornelia Fürstenberger, aus Basel, Schweiz Basel, 2014 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt (Fakultätsverantwortlicher) ________________________ Fakultätsverantwortlicher Prof. Dr. Alex Odermatt und Prof. Dr. Rik Eggen (Korreferent) ________________________ Korreferent Prof. Dr. Rik Eggen Basel, den 20. Mai 2014 ________________________ Dekan Prof. Dr. Jörg Schibler 2 Table of content Table of content I. Abbreviations ................................................................................................................................. 6 1. Summary ........................................................................................................................................ 9 2. Introduction .................................................................................................................................. 12 2.1 Steroid hormones .................................................................................................................. 12 2.2 Steroidogenesis ..................................................................................................................... 14 2.3 Steroid hormones in health and disease ..............................................................................
    [Show full text]
  • Original Article Genetic Polymorphisms in the Androgen Metabolism Pathway and Risk of Prostate Cancer in Low Incidence Malaysian Ethnic Groups
    Int J Clin Exp Med 2015;8(10):19232-19240 www.ijcem.com /ISSN:1940-5901/IJCEM0011564 Original Article Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups Prevathe Poniah1, Zahurin Mohamed2, Yamunah Devi Apalasamy2, Shamsul Mohd Zain2, Shanggar Kuppusamy1, Azad HA Razack1 Departments of 1Surgery, 2Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malay- sia Received June 17, 2015; Accepted September 22, 2015; Epub October 15, 2015; Published October 30, 2015 Abstract: Androgens are involved in prostate cancer (PCa) cell growth. Genes involved in androgen metabolism mediate key steps in sex steroid metabolism. This study attempted to investigate whether single nucleotide poly- morphisms (SNPs) in the androgen metabolism pathway are associated with PCa risk in low incidence Asian ethnic groups. We genotyped 172 Malaysian subjects for cytochrome P450 family 17 (CYP17A1), steroid-5-alpha-reduc- tase, polypeptide 1 and 2 (SRD5A1 and SRD5A2), and insulin-like growth factor 1 (IGF-1) genes of the androgen metabolism pathway and assessed the testosterone, dihydrotestosterone and IGF-1 levels. SNPs in the CYP17A1, SRD5A1, SRD5A2, and IGF-1 genes were genotyped using real-time polymerase chain reaction. Although we did not find significant association between SNPs analysed in this study with PCa risk, we observed however, signifi- cant association between androgen levels and the IGF-1 and several SNPs. Men carrying the GG genotype for SNP rs1004467 (CYP17A1) had significantly elevated testosterone (P = 0.012) and dihydrotestosterone (DHT) levels (P = 0.024) as compared to carriers of the A allele. The rs518673 of the SRD5A1 was associated with prostate spe- cific antigen (PSA) levels.
    [Show full text]